The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1733
July 21, 2025
View Complete Issue         Table of Contents 2019 
Issue 1733
Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
Berdazimer Gel (Zelsuvmi) for Molluscum Contagiosum
July 21, 2025 (Issue: 1733)
Berdazimer 10.3% gel (Zelsuvmi – Ligand), a first-in-class nitric oxide-releasing agent, has been approved by the FDA for topical treatment of molluscum contagiosum in patients ≥1 year old. It is the second drug to become available in the US...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1733
 


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.